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1. Introduction 
Ion channel dysfunction has been implicated in several neurological diseases including 
epilepsy. Cerebral ion channels, and particularly presynaptic channels controlling 
neurotransmitter release, are among the most important targets of various antiepileptic drugs.  
In comparison with other parts of the neuron, in presynaptic nerve endings Na+ and Ca2+ 
channels controlling neurotransmitter release are particularly abundant. However, most 
studies directed to test the effect of antiepileptic drugs on ion channels are done in 
preparations suitable for electrophysiological approaches. Because using those approaches 
in the small sized cerebral nerve endings is almost impossible.  
In the present chapter I describe the strategies that we have used for investigating the effects of 
several compounds known for their anticonvulsant properties, including several of the most 
commonly used antiepileptic drugs of the first and second generations, as well as of the new 
potential antiepileptic drug, vinpocetine on cerebral presynaptic ionic channels. For 
discriminating the effects of those compounds on presynaptic Na+ and Ca2+ channels, we first 
used depolarizing strategies, such as veratridine that triggers the entrance of Na+ by activation 
of cerebral presynaptic Na+ channels even when the participation of Ca2+ channels is 
eliminated, or such as a high external concentration of K+, that activates cerebral pre-synaptic 
Ca2+ channels even when the participation of Na+ channels is eliminated (Sitges & Galindo, 
2005; Sitges et al., 2007a; 2007b). More recently, we also test the effects of antiepileptic drugs in 
the cerebral nerve endings in vitro using 4-aminopyridine as depolarizing strategy. Because 4-
aminopyridine exposure may more closely mimic some of the changes that may take place in 
the epileptic tissue, since in cerebral nerve endings 4-aminopyridine besides increasing the 
permeability of Na+ and Ca2+ channels, also decreases the permeability of some K+ channels, 
and by this mean arrests indirectly the Na+/K+ ATPase (Galván & Sitges, 2004), making even 
more difficult the limitation of neuronal excitability.  
2. Effects of antiepileptic drugs on cerebral presynaptic Na+ channel mediated 
responses induced with veratridine  
Voltage sensitive Na+ channels are responsible for the initiation and conduction of neuronal 
action potentials. Therefore, the pharmacological down-modulation of those channels in 
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situations in which all neurons are firing, such as during epileptic seizures, is likely to be 
particularly beneficial.  
Several of the most effective antiepileptic drugs are believed to stop the paroxysmal 
neuronal activity acting as Na+ channel blockers. In comparison with other parts of the 
neuron, Na+ channels in presynaptic boutons are particularly abundant (Engel & Jonas, 
2005). Nonetheless since the small size of cerebral presynaptic boutons (< 0.3 µm) make 
electrophysiological approaches very difficult, most of the pioneer as well as the 
sophisticated and important actual studies directed to test the effect of antiepileptic drugs 
on Na+ channels were done in preparations suitable for electrophysiological approaches. 
These preparations include  molluscan giant axons, kidney cells and Chinese hamster ovary 
cells transfect with the alpha subunit (the pore moiety) of the channel, and cells in culture 
among others (Lipicky et al.,1972; Fohlmeister et al., 1984; Xie et al., 1995; Sun & Lin, 2000; 
Xie et al., 2001; Huang et al., 2006; Lenkey et al., 2010; Karoly et al., 2010); and there are only 
few studies in which the effect of antiepileptic drugs on presynaptic ion channels controlling 
neurotransmitter release in the brain were investigated.  
Among the first evidences suggesting an involvement of brain presynaptic Na+ channel 
blockade in the mechanism of action of some antiepileptic drugs, was the displacement of 3H-
batrachotoxin binding to Na+ channels in cerebral membranes and brain isolated nerve 
endings by the antiepileptic drugs carbamazepine, phenytoin and lamotrigine (Willow & 
Catterall, 1982; Cheung et al., 1992; Deffois et al., 1996; Bonifacio et al., 2001; Santangeli et al., 
2002; Lingamaneni & Hemmings, 2003). Batrachotoxin, like veratridine, is a toxin of natural 
origin that binds to the site 2 (voltage sensor) of the Na+ channel impeding its inactivation and 
by this mean increases the rate of Na+ entry and depolarizes the plasma membrane of cerebral 
isolated nerve endings (Krueger et al., 1980). With the aid of: SBFI, fura-2 and PBFI, that are 
selective indicator dyes which change their emission fluorescence in response to the changes in 
Na+, Ca2+ or K+ in its vicinity, respectively, the changes in those ion channel permeability can 
be monitored in cerebral isolated nerve endings. Using cerebral isolated nerve endings 
preloaded with the Na+ selective indicator dye, SBFI, we found that veratridine was able to 
increase the internal concentration of Na+ independently of the presence of external Ca2+ 
(Sitges et al., 1998). Figure 1 adapted from our previous work (Sitges & Galindo, 2005) shows 
that in hippocampus isolated nerve endings veratridine is still increasing Na+ when 
presynaptic Ca2+ channels are blocked by ω-agatoxin-TK but not when Na+ channels are 
blocked by tetrodotoxin, a toxin of natural origin that binds irreversible to the external pore of 
the Na+ channel (i.e. site 1) and by this mean blocks Na+ entrance into the cytoplasm. The 
hippocampus is a brain structure particularly involved in seizures. 
Cerebral isolated nerve endings (commonly referred to as synaptosomes) preserve many 
physiological properties of intact nerve terminals, including a tight coupling of 
neurotransmitter release to ion fluxes during depolarization (Turner et al., 1992; Sitges & 
Chiu, 1995a; 1995b; Sitges et al., 1998; Galván & Sitges, 2004). Depolarization-evoked 
neurotransmitter release, including the release of the excitatory amino acid neurotransmitter 
glutamate, the most abundant neurotransmitter in cerebral isolated nerve endings (Sitges et 
al., 2000), is composed by two fractions: a Ca2+ dependent fraction released by exocytosis 
and a Na+ dependent fraction released from the cytoplasm by reversal of the 
neurotransmitter transporters.  
When the internal concentration of Na+ is substantially elevated with toxins such as 
veratridine in the absence of external Ca2+ brain neurotransmitters can be released from the 
cytoplasm (Nicholls, 1989; Sitges 1989; Adam-Vizi, 1992; Sitges et al., 1993; 1994; Sitges & 
Chiu, 1995a; Sitges et al., 1998; Sitges & Galindo 2005). In hippocampus synaptosomes the 
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release of glutamate induced by veratridine in the absence of external Ca2+ was sensitive to 
the EAAT (excitatory amino acid transporter) inhibitor, TBOA (Fig. 2), indicating that the 
release of glutamate induced by veratridine originates from the cytoplasm by reversal of the 
neurotransmitter transporters located at the level of the presynaptic nerve endings.  
 
 
Fig. 1. The elevation of Na+ (in mM) induced by veratridine is insensitive to ω-agatoxin-TK 
and completely blocked by tetrodotoxin. In this and the following cartoons channels are 
represented like tubes, although they are trans-membrane proteins well characterized. 
 
 
Fig. 2. Inhibition exerted by the EAAT inhibitor, TBOA, on glutamate (Glu) release induced 
by the Na+ channel opener veratridine (arrow) via reversal of the glutamate transporter 
(Glu-t) in hippocampal synaptosomes.  
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Neurotransmitter release evoked by veratridine in synaptosomes isolated from the whole 
brain or different brain regions is also highly sensitive to the blockade of Na+ channels with 
tetrodotoxin and absolutely dependent on the presence of external Na+, but is independent 
of external Ca2+ (Sitges, 1989; Sitges & Chiu, 1995a; Galindo & Sitges, 2004; Sitges & Galindo, 
2005). This Ca2+ independence of veratridine induced responses is particularly valuable as it 
allows testing the inhibitory effect of compounds on responses selectively mediated by 
activation of presynaptic voltage sensitive sodium channels in the cerebral isolated nerve 
endings.  
The action of carbamazepine as a brain presynaptic Na+ channel blocker was first indicated 
by the sensitivity of the veratridine-induced release of glutamate to that antiepileptic drug 
(Ambrosio et al., 2001). In a previous study in cerebral nerve endings isolated from the 
hippocampus we compared the effect of increasing concentrations of several antiepileptic 
drugs, including carbamazepine, on the release of glutamate induced by veratridine in the 
absence of external Ca2+. Figure 3, adapted from our previous work (Sitges et al., 2007a; 
2007b), shows that the antiepileptic drugs: carbamazepine, phenytoin, lamotrigine and 
oxcarbazepine, progressively inhibit glutamate release induced by veratridine in a range 
from 150 to 1500 µM, whereas the antiepileptic drug topiramate only exerted a modest 
inhibition (20%) at the highest concentration tested (1500 µM). Interestingly, valproate 
which mechanism of action has been related to the increase in GABAergic transmission 
(Loscher 2002) was unable to inhibit glutamate release to veratridine at all, although a very 
large range of valproate concentrations was tested.  
 
 
Fig. 3. Inhibition (in percentage of control) exerted by several antiepileptic drugs at 
increasing concentrations on glutamate (Glu) release induced by veratridine in 
hippocampus synaptosomes. 
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Results in figure 3 indicate that blockade of presynaptic Na+ channels permeability 
contributes to the anticonvulsive action of carbamazepine, phenytoin, lamotrigine and 
oxcarbazepine, but not to the anticonvulsive action of topiramate or valproate.  
3. Effects of antiepileptic drugs on high K+ induced responses 
On the basis of electrophysiological studies in dissociated cells, neurons in culture or brain 
slices also a reduction of Ca2+ channels permeability by several of the most effective 
antiepileptic drugs was suggested (Schirrmacher et al., 1993; Lees & Leach, 1993; Wang et al., 
1996; Stefani et al., 1996; 1997; Kuzmiski et al., 2005). However, Ca2+ currents obtained in those 
preparations not necessarily reflect the effect of antiepileptic drugs on brain presynaptic Ca2+ 
channels controlling neurotransmitter release. Because in cell bodies, dendrites and nerve 
endings different types of calcium channels were localized (Timmerman et al., 2001), and Ca2+ 
currents obtained in the above preparations must be mainly somatic.  
Again, as for the case of cerebral presynaptic ion Na+ channels, cerebral presynaptic Ca2+ 
channels cannot be easily approached with electrophysiological techniques because of the 
small size of cerebral nerve endings. Nevertheless, with the selective Ca2+ indicator dye, 
fura-2, the changes in the internal concentration of Ca2+ concomitant to the changes in 
cerebral presynaptic Ca2+ channels permeability can be monitored directly in the cerebral 
isolated nerve endings.  Using this technique it has been shown that among the several 
types of Ca2+ channels present in neurons, those sensitive to ω-agatoxin-IVA and to ω-
agatoxin-TK, two peptides isolated from the venom of the spider Agelenopsis aperta, were 
particularly implicated in neurotransmitter release from cerebral nerve endings (Turner et 
al., 1992; Sitges & Chiu, 1995a; 1995b; Carvalho et al., 1995; Sitges & Galindo, 2005).  P/Q 
type Ca2+ channels are pharmacologically characterized by their sensitivity to the above 
mentioned ω-agatoxins. In line, the cloned neuronal Ca2+ channel α1Asubunit encoding Ca2+ 
channels of the P/Q type was localized at a high density in presynaptic nerve terminals of 
many neurons (Westenbroek et al., 1995).  
 
 
Fig. 4. The rise in Ca2+ induced by high K+ depends on presynaptic Ca2+ channels 
availability and the rise in Ca2+ induced by veratridine depends on Na+ channels availability 
(this figure was adapted from Sitges & Galindo (2005) 
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The top graph in figure 4 shows the increase in Ca2+ induced by high K+ depolarization 
followed by the increase in Ca2+ induced by veratridine depolarization in hippocampal 
synaptosomes under control conditions. The middle graph shows the failure of high K+ 
depolarization to increase Ca2+ when Ca2+ channels are blocked by ω-agatoxin-TK and the 
failure of this blockade to prevent the veratridine induced increase in Ca2+.  Oppositely, the 
bottom graph shows that when Na+ channels are blocked by tetrodotoxin, high K+ 
depolarization is still increasing Ca2+, but veratridine does not. 
It is important to mention that in the presence of external Ca2+, veratridine depolarization 
also can increase the internal concentration of Ca2+ like high K+ depolarization. Nonetheless, 
the underlying mechanisms are different. Because while the entrance of external Na+ via 
tetrodotoxin sensitive Na+ channels is strictly required for the increase in Ca2+ and the 
increase in neurotransmitter release induced by veratridine, the increase in Ca2+ induced by 
high K+ is insensitive to the absence of external Na+ or to the presence of tetrodotoxin (Sitges 
& Chiu, 1995a; Sitges et al., 1998; Sitges & Galindo 2005). 
In the absence of Na+ or in the presence of tetrodotoxin, high K+ depolarization also is still 
increasing neurotransmitter release. In hippocampus isolated nerve endings the fraction of 
glutamate release induced by high K+ depolarization in the absence of external Na+, 
however, is completely dependent on external Ca2+ and is highly sensitive to nanomolar 
concentrations of ω-agatoxin-IVA and ω-agatoxin-TK, as  shown in figure 5 adapted from 
Sitges & Galindo (2005). This figure shows that high K+ depolarization induced responses in 
the absence of external Na+ are directly linked to the inhibition of cerebral presynaptic Ca2+ 
channels permeability. 
 
 
Fig. 5. Glutamate (Glu) release induced by high K+ depends on the presence of external Ca2+ 
and is sensitive to the P/Q type Ca2+ channel blocker toxins. This figure was adapted from 
Sitges & Galindo (2005). 
Since high K+ can selectively release the Ca2+ dependent fraction of neurotransmitter release 
by exocytosis, for investigating the action of antiepileptic drugs on cerebral presynaptic Ca2+ 
channels permeability, we tested their effects at increasing concentrations on the Ca2+ 
channel-mediated release of glutamate evoked by high K+ in the absence of external Na+ in 
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hippocampus isolated nerve endings. Figure 6, adapted from Sitges et al. (2007b), shows that 
carbamazepine, phenytoin and oxcarbazepine only reduced in about 30% and 55% 
glutamate release to high K+ at concentrations of 500 µM and 1500 µM, respectively; that 
lamotrigine and topiramate were even less effective, as at the highest concentration tested 
(1500 µM) they only exerted a mild reduction (about 25%) of glutamate release to high K+, 
and that valproate failed to modify the K+ response at all. These results indicate that only 
some of the antiepileptic drugs tested, namely carbamazepine, phenytoin and 
oxcarbazepine, are able to reduce cerebral presynaptic Ca2+ channels permeability in some 
degree at high doses.  
 
 
Fig. 6. Inhibition (in percentage of control) exerted by the indicated antiepileptic drug at 
increasing concentrations on glutamate (Glu) release induced by high K+ in hippocampus 
synaptosomes. 
4. Effects of antiepileptic drugs on 4-aminopyridine induced responses 
4-aminopyridine is a convulsing agent that induces epileptiform activity in brain slices in 
vitro as in animal models of epilepsy in vivo (Ives & Jefferys, 1990; Perreault & Avoli, 1991; 
Yamaguchi & Rogawski, 1992; Psarropoulou & Avoli, 1996; Armand et al., 1999; 
Nekrassov & Sitges, 2003). 4-aminopyridine increases neurotransmitters release, including 
glutamate, the most important excitatory amino acid neurotransmitter in the brain, that is 
by far the most concentrated neurotransmitter in cerebral isolated nerve endings (Sitges et 
al., 2000).   
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The action of 4-aminopyridine at the brain presynaptic level is amply documented. 
Although the rise in the internal concentration of Ca2+ induced by 4-aminopyridine was 
not resolved using 45Ca2+ (Tapia et al., 1985), it became evident when the more sensitive 
fura-2 technique was used in cerebral isolated nerve endings.  The  role of voltage 
sensitive sodium channels in the mode of action of 4-aminopyridine, first suggested by 
the sensitivity of the Ca2+ response induced by 4-aminopyridine to the Na+ channel 
blocker, tetrodotoxin (Tibbs et al., 1989; Heemskerk et al., 1991) was later demonstrated in 
cerebral isolated nerve endings using the Na+ selective indicator dye, SBFI (Galván & 
Sitges 2004). The involvement of K+ channels in the mode of action of 4-aminopyridine at 
the presynaptic brain level, first suggested by the changes on 86Rb+ fluxes in brain nerve 
endings (Sitges et al., 1986), was confirmed later using the K+ selective indicator dye, PBFI 
(Galindo & Sitges 2004). In summary, in cerebral isolated nerve endings 4-aminopyridine 
increases Na+ channels permeability (Galván and Sitges, 2004), Ca2+ channels permeability 
(Tibbs et al., 1989; Heemskerk et al., 1991; Galván & Sitges, 2004; Sitges et al., 2005), and 
decreases K+ channels permeability (Sitges et al., 1986; Galván & Sitges, 2004). Therefore, 
the changes that may occur in cerebral nerve endings under the excitatory conditions that 
take place during seizures seem to be more closely resembled by 4-aminopyridine; 
although its mechanism of action is complicated. For instance, in contrast to veratridine, 
that can increase Na+ and glutamate release independently of Ca2+ channels activation, or 
in contrast to high K+ that can increase Ca2+ and glutamate release independently of Na+ 
channels activation (Sitges & Galindo, 2005; Sitges et al., 2007a; 2007b), 4-aminopyridine is 
unable to increase Ca2+ and to induce glutamate exocytosis, when Na+ channels are 
blocked by tetrodotoxin (Tibbs et al., 1989; Heemskerk et al., 1991; Galván & Sitges, 2004; 
Sitges et al., 2005). Thus, as the tetrodotoxin-sensitive fraction of glutamate release 
induced by 4-aminopyridine requires the presence of external Ca2+ and is sensitive to 
presynaptic Ca2+ channel blockade, the tetrodotoxin-sensitive fraction of glutamate 
release induced by 4-aminopyridine is expected to be the fraction released from the 
vesicular pool by exocytosis. This also contrasts with veratridine depolarization, that 
increases glutamate release in a tetrodotoxin sensitive manner via reversal of the 
neurotransmitter transporter independently of presynaptic Ca2+ channels, and with high 
K+ depolarization that increases Ca2+ and glutamate exocytosis from the vesicular pool in 
a tetrodotoxin insensitive manner independently of presynaptic Na+ channels (Sitges & 
Galindo, 2005; Sitges et al. 2007a; 2007b).  Moreover, in addition to the tetrodotoxin-
sensitive increases in Na+, Ca2+ and glutamate exocytosis, 4-aminopyridine also produces 
an accumulation of Na+ that is tetrodotoxin insensitive and is accompanied by a decrease 
in the internal concentration of K+, due to inhibition of the Na/K-ATPase that restores K+ 
(Galván & Sitges, 2004). This tetrodotoxin insensitive accumulation of Na+, that is 
independent of presynaptic Na+ or Ca2+ channels activation, is likely to also release the 
cytoplasm fraction of glutamate by reversal of the glutamate transporter in a tetrodotoxin 
insensitive manner. 
Figure 7 shows that the maximal inhibitory effect on glutamate release to 4-aminopyridine 
exerted by the antiepileptic drugs: carbamazepine, phenytoin, lamotrigine and 
oxcarbazepine in a range from 75 to 750 µM in hippocampus isolated nerve endings, that is 
almost reached with the concentration of 250 µM, is not larger than 50-60%. Similarly 1 µM 
tetrodotoxin also inhibited glutamate released to 4-aminopyridine only in about 50%; and at 
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that concentration tetrodotoxin completely abolished the veratridine-induced responses in 
synaptosomes, indicating that the decrease in glutamate release to 4-aminopyridine exerted 
by the above antiepileptic drugs, is linked to the blockade of presynaptic Na+ channels. 
Figure 7 also shows that topiramate at the highest concentration tested (750 µM) only 
exerted a modest inhibition of 4-aminopyridine induced glutamate release; further 
indicating that the anticonvulsant mechanism of action of that antiepileptic drug is 
unrelated with a reduction in cerebral presynaptic Na+ channels permeability. In line with 
this last interpretation previous studies showed that neuronal Na+ currents were only 
slightly reduced by topiramate at high doses (Zona et al., 1997; Taverna et al., 1999; Mc. 
Lean et al., 2000). 
 
 
Fig. 7. Inhibition (in percentage of control) exerted by the indicated compounds at increasing 
concentrations on glutamate (Glu) release induced by 4-aminopyridine in hippocampus 
synaptosomes. 
Figure 8 shows that similarly to glutamate release induced by 4-aminopyridine, the rise in 
Ca2+ induced by 4-aminopyridine also was partially sensitive to the blockade of Na+ 
channels with 1 µM tetrodotoxin or with 250µM carbamazepine, phenytoin, lamotrigine and 
oxcarbazepine, and insensitive to topiramate at that concentration. 
The antiepileptic drugs valproate and levetiracetam, even at a very high (1000 µM) 
concentration were unable to inhibit the rise in Ca2+ induced by 4-aminopyridine in 
hippocampus isolated nerve endings. In line,  levetiracetam,  like valproate, also was unable 
to inhibit glutamate release induced by the Na+ channel opener, veratridine or by high K+ 
(data not shown), suggesting that levetiracetam mechanism of action does not involve 
inhibition of cerebral presynaptic Na+ or Ca2+ channels permeability as well. 
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Fig. 8. The elevation of Ca2+ (in mM) induced by 4-aminopyridine in hippocampus isolated 
nerve endings is sensitive to carbamazepine (CBZ), lamotrigine (LTG), phenytoin (PHT), 
oxcarbazepine (OxCBZ) and tetrodotoxin (TTX), and insensitive to topiramate (Top). 
5. Presynaptic Na+ channels are better targets of antiepileptic drugs than 
presynaptic Ca2+ channels 
Comparison of the inhibition exerted by the antiepileptic drugs on glutamate release 
triggered by the selective activation of Ca2+ channels with high K+ with the inhibition 
exerted by the antiepileptic drugs on glutamate release evoked by the activation of Na+ 
channels induced by veratridine, clearly shows that antiepileptic drugs targeting cerebral 
presynaptic channels are in general more effective blockers of presynaptic Na+ than of 
presynaptic Ca2+ channel mediated responses.  
Moreover, it is likely that all the compounds that inhibited the increase in Ca2+ and the 
release of glutamate induced by 4-aminopyridine were reducing presynaptic Na+ channels 
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permeability, and by this mean the entrance of Ca2+. In agreement with this conclusion, 
lamotrigine that barely reduced the Ca2+ dependent release of glutamate induced by high K+ 
(Fig. 6), markedly inhibited glutamate release induced by veratridine (Fig. 3). Thus, the 
inhibition exerted by lamotrigine on the rise in Ca2+ induced by 4-aminopyridine may also 
result from a blockade of tetrodotoxin sensitive Na+ channels. In line with an indirect effect 
of lamotrigine, as well as of carbamazepine, on the rise in Ca2+ induced by 4-aminopyridine, 
a detailed model of the binding sites for carbamazepine, lamotrigine and phenytoin in the 
inner pore of voltage-gated Na+ channels was recently provided by Lipkind and Fozzard 
(2010). 
6. Effect of the new potential antiepileptic drug vinpocetine on presynaptic 
ion channels 
Although there is an uncovered medical need for the treatment of epilepsies, neurologists 
are with reasons reluctant to believe in new antiepileptic drugs. Because also new 
antiepileptic drugs produce several secondary effects that in some cases are severe. In 
addition to the fact that as antiepileptic drugs control seizures but do not cure the illness, 
they have to be taken for all the life span. 
Vinpocetine (ethyl apovincamine-22-oate) is a nootropic drug with neuroprotective 
capabilities discovered during the late 1960s that in animal models of hypoxia and ischemia 
exerts beneficial effects against neuronal damage and has been used in the treatment of 
central nervous system disorders of cerebral-vascular origin for decades. In brain isolated 
nerve endings vinpocetine inhibited the rise in the internal concentration of Na+ and 
neurotransmitter release induced by veratridine (Tretter & Adam-Vizi, 1998; Sitges & 
Nekrassov, 1999; Trejo et al., 2001; Sitges et al., 2006), as well as the tetrodotoxin sensitive 
fraction of the rise in Na+ and Ca2+ induced by 4-aminopyridine (Sitges et al., 2005). In 
hippocampus isolated nerve endings, vinpocetine inhibited glutamate release induced by 
increasing presynaptic Na+ channels permeability with veratridine and by increasing 
presynaptic Ca2+ channels permeability with high K+ in a much lower range of 
concentrations than carbamazepine, phenytoin, lamotrigine and oxcarbazepine (Sitges et al., 
2007a; 2007b).  
Moreover, in contrast to carbamazepine, phenytoin, lamotrigine and oxcarbazepine, which 
that at the highest dose tested (750 µM) only inhibited glutamate release to 4-aminopyridine 
between 50-60%, vinpocetine completely abolished glutamate release to 4-aminopyridine at 
a concentration of 25 µM, which is a much lower concentration. Since in molluscan neurons, 
30 µM vinpocetine, but not other antiepileptic drugs, increases the fast inactivating 4-
aminopyridine-sensitive K+ current (IA) (Bukanova et al., 2002), one possible explanation of 
the higher efficacy of vinpocetine to inhibit glutamate release induced by 4-aminopyridine 
in the hippocampus nerve endings could be that, in addition to its action on Na+ and Ca2+ 
channels, vinpocetine is capable to overcome the blockade of the IA current produced by 4-
aminopyridine. Also at a tenfold lower concentration than of carbamazepine, phenytoin, 
lamotrigine and oxcarbazepine, vinpocetine reduced the Ca2+ response to 4-aminopyridine 
in hippocampus isolated nerve endings. Figure 9 summarizes some of the above findings. 
Combination of antiepileptic drugs is a common practice in refractory epileptics not 
responding to mono-therapy. Interestingly, in striatum isolated nerve endings vinpocetine 
facilitated the inhibition exerted by carbamazepine on the rise in Na+ and glutamate release 
induced by veratridine activation of Na+ channels (Sitges et al., 2006).  
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Fig. 9. Inhibition (in percentage of control) exerted by vinpocetine at increasing 
concentrations on the release of glutamate (Glu) induced by: veratridine, high K+ and 4-
aminopyridine, and on the elevation of Ca2+ induced by 4-aminopyridine in hippocampus 
synaptosomes. 
7. Comparison of vinpocetine and some antiepileptic drugs effects on seizures 
and hearing in the animal in vivo 
The high antiepileptic potential of vinpocetine also was evidenced in the guinea pig in vivo; 
where vinpocetine completely prevented seizures and the epileptic-like cortical activity 
induced by 4-aminopyridine at a convulsive dose (Sitges & Nekrassov, 2004).  
The top traces in figures 10a and 10b show that the EEG recordings under control conditions 
(i.e. before the injection of the convulsive agent, 4-aminopyridine) in an animal administered 
with vehicle and an animal administered with vinpocetine are similar. In contrast, the 
abnormal EEG changes accompanying seizures observed 20, 30, 60 and 80 min after 4-
aminopyridine administration in the control animal administered with vehicle are not 
observed in the animal pre-administered with 2 mg/kg vinpocetine. 
Also seizures and the epileptiform activity induced by the convulsive agent 
pentylenetetrazole were vinpocetine sensitive (Nekrassov & Sitges, 2004). Representative 
EEG recordings before and 10, 20, 30 and 50 min after pentylenetetrazole administration are 
shown in figure 11a, and representative EEG recordings before and at the same periods of 
time after pentylenetetrazole administration in an animal pre-administered with vinpocetine 
are in figure 11b.  
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Fig. 10. Representative EEG recordings of the cortical activity before and at the indicated 
times after 4-aminopyridine in: (a) a control animal and (b) an animal pre-administered with 
vinpocetine.  
 
 
Fig. 11. Vinpocetine prevents pentylenetetrazole-induced epileptiform activity 
accompanying seizures. 
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Moreover, the epileptiform activity accompanying seizures induced by pentilenetetrazole 
was inhibited by vinpocetine at a lower dose than the classical antiepileptic drugs: 
carbamazepine, phenytoin and valproate (Nekrassov & Sitges, 2006), and a higher potency 
of vinpocetine than carbamazepine to inhibit seizures induced by 4-aminopyridine was 
observed too (Nekrassov & Sitges, 2008).  
In a previous study, in which the acute, chronic and post-treatment effects of carbamazepine 
and vinpocetine were investigated on seizures induced by 4-aminopyridine in the guinea 
pig in vivo (Nekrassov & Sitges 2008) we found that: all the control animals developed 
seizures upon 4-aminopyridine exposure regardless on the time of vehicle administration; 
namely vehicle injection one hour before 4-aminopyridine (acute), 13 days of vehicle 
injections before 4-aminopyridine (chronic) or 4-aminopyridine one month after the end of 
the vehicle injections (post-treatment), as illustrated in figure 12a adapted from Nekrassov & 
Sitges, 2008. We also found that in the carbamazepine animal group, the acute 
carbamazepine treatment failed to prevent 4-aminopyridine-induced seizures in all the  
animals, whereas the chronic carbamazepine treatment, protected about half of the animals 
from developing seizures after 4-aminopyridine. However, one month after the end of 
treatment, all the animals of the carbamazepine group developed seizures again after 4-
aminopyridine (Fig. 12b). In the vinpocetine animal group, the acute vinpocetine treatment 
already protected 43% of the animals from developing seizures and the chronic vinpocetine 
treatment 70% of the animals.  Interestingly, 40% of the animals in the vinpocetine group 
did not developed seizures upon 4-aminopyridine administration one month after the end 
of treatment (Fig. 12c).  
 
 
Fig. 12. Acute, chronic and post-treatment effects of carbamazepine and vinpocetine on 
seizures induced by 4-aminopyridine at a highly convulsive dose. Guinea pigs presenting 
seizures (in percentage) after the injection of 4-aminopyridine before any treatment was 
started (bef.), one hour after the first (1h) or of the last (13 d) injection of:  (a) vehicle, (b) 17 
mg/kg carbamazepine or (c) 3 mg/kg vinpocetine, and one month after the end of the 
above treatments (post).   
Since the available antiepileptic drugs control seizures but do not cure the illness, the 
finding that vinpocetine even after post-treatment was able to prevent 4-aminopyridine-
induced seizures is very hopefulness. 
In another study, (Nekrassov & Sitges, 2006) we also investigated the auditory sensitivity, as 
indicated by brainstem auditory evoked potential thresholds at two tone frequencies (4 and 
8 kHz) in guinea pigs daily injected with vehicle (control), 20 mg/kg carbamazepine, 6 
mg/kg phenytoin, 30 mg/kg valproate or 2 mg/kg vinpocetine for 28 days before and after 
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the administration of pentylenetetrazole at a convulsing dose (100 mg/kg). In that study we 
found that the long term treatment with carbamazepine, phenytoin or valproate increased 
the auditory threshold to a similar extent as the convulsing agent, pentylenetetrazole. In 
contrast, the 28 days treatment with vinpocetine even decreased the auditory threshold. 
Moreover, the increases exerted by the antiepileptic drugs and by pentylenetetrazole on the 
auditory thresholds were additive, indicating that the hearing loss produced by the long 
term treatment with the most commonly used antiepileptic drugs could be aggravated by 
the illness. On the contrary, vinpocetine at the anticonvulsive dose prevented the hearing 
decline accompanying seizures. In other words, oppositely to the classical antiepileptic 
drugs carbamazepine, phenytoin and valproate, vinpocetine was able to improve hearing 
loss by itself and to prevent hearing loss accompanying seizures (Nekrassov & Sitges, 2006). 
Figure 13 adapted from data reported in : (a) Nekrassov & Sitges, 2004 and (b) Sitges & 
Nekrassov, 2004 shows that vinpocetine pre-administered at a dose of 2 mg/kg (i.p.) 
prevents the hearing loss induced by pentylenetetrazole and 4-aminopyridine at convulsive 
doses in the guinea pig in vivo. Hearing loss was assessed by recording the auditory 
threshold at 8 kHz before, 30 and 60 min after administration of the convulsive agents.  
 
 
Fig. 13. Vinpocetine inhibits the rise in the auditory threshold induced by pentylenetetrazole 
(PTZ) and 4-aminopyridine (4-AP) at convulsive doses. 
The high doses of antiepileptic drugs required to control seizures are frequently 
accompanied by adverse secondary effects. A great number of epileptic patients suffer from 
memory disturbances which are consequence of both, the disease (Prevey et al., 1998; 
Theodore et al., 1999; Meador, 2001; Elger et al., 2004) and the antiepileptic medication; as 
several studies show that antiepileptic drugs of either the “old and new generations” are 
also a causal factor (Vermeulen & Aldenkamp, 1995; Gates, 2000; Kwan & Brodie, 2001; 
Brunbech & Sabers, 2002; Schmidt, 2002). For instance, the classic antiepileptic drug 
carbamazepine deteriorates cognitive function particularly when administered at high doses 
or after a long term treatment (O´Dougherty et al., 1987; Gallassi et al., 1988; Forsythe et al., 
1991; van der Meyden et al., 1992; Seidel & Mitchell, 1999). Fascinatingly previous studies in 
animals and humans show that vinpocetine is also a memory enhancer (Subhan & 
Hindmarch, 1985; Bhatti & Hindmarch, 1987; DeNoble, 1987: Lendvai et al., 2003). 
The higher potency of vinpocetine not necessarily has to indicate a best side-effect profile 
than the conventional antiepileptic drugs. Nevertheless, vinpocetine has shown to be well 
tolerated and without contraindications (Hindmarch et al., 1991). Therefore, the higher 
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potency and efficacy of vinpocetine to reduce the permeability of presynaptic ionic channels 
controlling the release of the most important excitatory neurotransmitter in the brain must 
be advantageous in seizures control and epilepsy treatment. In line with this assumption it 
is worthy to mention that an unpublished investigation in course in epileptic children 
resistant to classic antiepileptic drugs the add-on-therapy of vinpocetine effectively 
controlled seizures at a dose more than tenfold lower than the dose of the classical 
antiepileptic drugs. 
8. Conclusion 
The findings summarized in the present chapter show that cerebral presynaptic ion 
channels, and particularly presynaptic Na+ channels controlling glutamate release, are 
among the most important targets of various anticonvulsant drugs. Therefore, the 
pharmacological down-modulation of those channels in situations in which all neurons are 
firing is likely to be particularly beneficial in the control of epileptic seizures.  In addition, 
since there is an uncovered medical need for the treatment of epilepsies and cerebral 
presynaptic channels are targets of the most effective antiepileptic drugs, the in vitro 
techniques presented in this chapter may represent powerful tools for the future screening 
and discover of anticonvulsive drugs controlling excitation by targeting brain presynaptic 
channels. The findings presented also show that the higher potency and efficacy of 
vinpocetine than the most effective antiepileptic drugs to inhibit presynaptic Na+ and Ca2+ 
channels permeability is extensive to the control of seizures in experimental animal models 
of epilepsy. Current unpublished studies carried out in epileptic inpatients refractory to the 
classic antiepileptic drugs also show the high efficacy of this third generation antiepileptic 
drug in seizures control.  
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